Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Up 70.8% in January

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totaling 274,164 shares, an increase of 70.8% from the December 31st total of 160,518 shares. Currently, 19.6% of the company’s shares are short sold. Based on an average daily trading volume, of 1,037,269 shares, the days-to-cover ratio is currently 0.3 days. Based on an average daily trading volume, of 1,037,269 shares, the days-to-cover ratio is currently 0.3 days. Currently, 19.6% of the company’s shares are short sold.

Shuttle Pharmaceuticals Price Performance

Shares of Shuttle Pharmaceuticals stock opened at $2.02 on Monday. The firm has a market cap of $3.23 million, a PE ratio of -0.17 and a beta of -1.03. Shuttle Pharmaceuticals has a 1 year low of $1.26 and a 1 year high of $19.95. The stock has a fifty day moving average price of $1.77 and a 200-day moving average price of $2.86.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last released its earnings results on Thursday, November 13th. The company reported ($1.05) earnings per share for the quarter.

Wall Street Analyst Weigh In

SHPH has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Shuttle Pharmaceuticals to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Shuttle Pharmaceuticals in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Shuttle Pharmaceuticals presently has an average rating of “Sell”.

Institutional Trading of Shuttle Pharmaceuticals

An institutional investor recently bought a new position in Shuttle Pharmaceuticals stock. Connective Capital Management LLC acquired a new stake in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) in the third quarter, according to its most recent filing with the SEC. The fund acquired 100,535 shares of the company’s stock, valued at approximately $357,000. Connective Capital Management LLC owned approximately 9.40% of Shuttle Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 4.58% of the company’s stock.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .